We are rapidly translating our specific, efficient and versatile CRISPR/Cas9 gene-editing platform into therapies to treat hemoglobinopathies, cancer, diabetes and other diseases
Our multi-disciplinary team of world-class researchers and drug developers works every day to translate our CRISPR/Cas9 technology into breakthrough human therapeutics. Our lead program targeting the blood diseases β-thalassemia and sickle cell disease has entered clinical testing, as has our first allogeneic CAR-T program targeting B-cell malignancies. We are also advancing additional blood stem cell, immuno-oncology, regenerative medicine and in vivo programs towards the clinic.
Building a great company with a focus on science, innovation, collaboration and entrepreneurship
Our revolutionary technology provides the foundation for building a sustainable innovation engine and a place to foster entrepreneurship across all fronts. We’re always looking for talented, experienced and passionate individuals to join us. We have our headquarters in Zug, Switzerland, our R&D operations in Cambridge, Massachusetts, USA and select business operations in London, United Kingdom. Please visit the careers page for more information.